New U.S. inversion rules threaten Pfizer-Allergan deal
WASHINGTON/NEW YORK (Reuters) - The U.S. Treasury Department took new steps on Monday to curb tax-avoiding corporate "inversions," with the pending $160 billion merger of Pfizer Inc and Allergan Plc seen as a potential casualty.
No comments:
Post a Comment